Guardant Health, Inc. (GH) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $160.89 (+6.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Luke Sergott | Barclays | $115.00 | -28.5% |
| Feb 17, 2026 | Catherine Schulte | Robert W. Baird | $120.00 | -25.4% |
| Jan 5, 2026 | Subbu Nambi | Guggenheim | $115.00 | -28.5% |
| Jan 5, 2026 | Vijay Kumar | Evercore ISI | $105.00 | -34.7% |
| Dec 15, 2025 | Brandon Couillard | Wells Fargo | $120.00 | -25.4% |
| Dec 1, 2025 | Tejas Savant | Morgan Stanley | $130.00 | -19.2% |
| Oct 30, 2025 | Dan Leonard | UBS | $110.00 | -31.6% |
| Oct 30, 2025 | Mark Massaro | BTIG | $100.00 | -37.8% |
| Oct 30, 2025 | Bradley Bowers | Mizuho Securities | $100.00 | -37.8% |
| Oct 30, 2025 | Kyle Mikson | Canaccord Genuity | $100.00 | -37.8% |
| Sep 26, 2025 | Kyle Mikson | Canaccord Genuity | $75.00 | -53.4% |
| Sep 25, 2025 | Mark Massaro | BTIG | $80.00 | -50.3% |
| Sep 25, 2025 | Daniel Arias | Stifel Nicolaus | $73.00 | -54.6% |
| Sep 25, 2025 | Doug Schenkel | Wolfe Research | $75.00 | -53.4% |
| Jun 25, 2025 | Tempus AI | China Renaissance Securities (US) Inc. | $70.00 | -56.5% |
| Aug 21, 2024 | Dan Leonard | UBS | $40.00 | -75.1% |
| Aug 8, 2024 | Bill Bonello | Craig-Hallum | $37.00 | -77.0% |
| Aug 8, 2024 | Tycho Peterson | Jefferies | $40.00 | -75.1% |
| Jul 29, 2024 | Mark Massaro | BTIG | $50.00 | -68.9% |
| Jun 28, 2024 | Subbu Nambi | Guggenheim | $36.00 | -77.6% |
Top Analysts Covering GH
GH vs Sector & Market
| Metric | GH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 33 | 8 | 19 |
| Target Upside | +11.1% | +16316.2% | +17.1% |
| P/E Ratio | -25.69 | 3.03 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.26B | $1.27B | $1.28B | 17 |
| 2027-03-31 | $355M | $363M | $370M | 6 |
| 2027-06-30 | $387M | $396M | $404M | 6 |
| 2027-09-30 | $416M | $425M | $434M | 6 |
| 2027-12-31 | $444M | $453M | $463M | 6 |
| 2028-03-31 | $438M | $447M | $456M | 5 |
| 2028-06-30 | $482M | $492M | $502M | 5 |
| 2028-09-30 | $541M | $552M | $564M | 6 |
| 2028-12-31 | $572M | $584M | $596M | 8 |
| 2029-12-31 | $2.51B | $2.56B | $2.70B | 11 |
| 2030-12-31 | $3.01B | $3.07B | $3.24B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-3.51 | $-2.96 | $-2.74 | 12 |
| 2027-03-31 | $-0.49 | $-0.48 | $-0.47 | 4 |
| 2027-06-30 | $-0.42 | $-0.41 | $-0.40 | 5 |
| 2027-09-30 | $-0.31 | $-0.30 | $-0.29 | 8 |
| 2027-12-31 | $-0.26 | $-0.26 | $-0.25 | 4 |
| 2028-03-31 | $-0.17 | $-0.17 | $-0.17 | 5 |
| 2028-06-30 | $-0.02 | $-0.02 | $-0.02 | 7 |
| 2028-09-30 | $0.26 | $0.27 | $0.27 | 10 |
| 2028-12-31 | $0.25 | $0.26 | $0.26 | 5 |
| 2029-12-31 | $1.05 | $1.08 | $1.16 | 6 |
| 2030-12-31 | $2.34 | $2.40 | $2.58 | 6 |
Frequently Asked Questions
What is the analyst consensus for GH?
The consensus among 33 analysts covering Guardant Health, Inc. (GH) is Buy with an average price target of $152.93.
What is the highest price target for GH?
The highest price target for GH is $160.00, set by Matthew Sykes at Goldman Sachs on 2021-06-03.
What is the lowest price target for GH?
The lowest price target for GH is $28.00, set by Chase Knickerbocker at Craig-Hallum on 2024-04-24.
How many analysts cover GH?
33 analysts have issued ratings for Guardant Health, Inc. in the past 12 months.
Is GH a buy or sell right now?
Based on 33 analyst ratings, GH has a consensus rating of Buy (2.00/5) with a +11.1% upside to the consensus target of $152.93.
What are the earnings estimates for GH?
Analysts estimate GH will report EPS of $-2.96 for the period ending 2026-12-31, with revenue estimated at $1.27B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.